Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on HIV Transcriptase

Posted by Matt Breese on Feb 28, 2017

Find me on:

According to our recent payer coverage analysis for HIV transcriptase inhibitors, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: Commercial and health exchange formularies look nearly identical when it comes to average product access and restrictions. When we take a deeper look at restrictions over the past quarter, prior authorizations became slightly more prevalent and restrictive to FDA approved labels.


MMIT-reality-check-hiv-1q2017.png

Source: MMIT data as of Q1 2017

Trends:  Recent news related to HIV treatments reveals the physician and patient perspective on therapy. The results from a recent phase 3 trial shows promise when it comes to simplifying HIV combination therapies. For instance, a 2-product combination in development could be as effective as existing 3 or 4-product combinations. We've also called out before how HIV awareness is improving with the use of social media and advocacy groups. 

In the full Reality Check on HIV transcriptase treatments below, MMIT's team of experts takes a deeper look into the clinical characteristics, drug market access and payer coverage to summarize key findings within the class.

To read the full Reality Check on HIV treatments with key findings on clinical characteristics, HIV drug market access and payer coverage, please click on the button below: 

reality-check-thumbnail-v1-1.png

View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing